To address this gap, we conducted a systematic review and meta-analysis to evaluate the efficacy and safety of pembrolizumab in PD-L1-positive advanced NSCLC, with a particular focus on clinical and molecular predictors of response. Here, CD274 is linked to non-small cell lung carcinoma.